Aerovate Therapeutics, Inc. — Form D
Aerovate Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-01-08. The offering totals $2.5M, of which $2.5M was reported sold. Industry: Other Technology.
Offering
- Filed: 2020-01-08
- Form: D
- Accession: 0001798749-20-000001
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $2.5M
- Amount sold: $2.5M
- Investors: 3
- Date of first sale: 2019-12-30
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-357485
Issuer
- Name: Aerovate Therapeutics, Inc.
- CIK: 0001798749
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: C/O RA CAPITAL MANAGEMENT, BOSTON, MA, 02116
- Phone: 617-778-2494
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Andrew Levin | Director | BOSTON, MA |
| Joshua Resnick | Director | New York, NY |
| Benjamin Dake | Executive Officer | Boston, MA |
| James Schneider | Executive Officer | Boston, MA |
| Maha T Katabi | Director | Boston, MA |
| Benjamin T Dake | Director | Boston, MA |
| Benjamin T Dake | Executive Officer | Boston, MA |
| Joshua T Resnick | Director | Boston, MA |
| Jonathan T Leff | Director | Boston, MA |
| David T Grayzel | Director | Boston, MA |
Other filings by this issuer (1)
More